placebo + cisplatin + carboplatin + 5-fluorouracil

This is a combination regimen consisting of placebo, cisplatin, carboplatin, and 5-fluorouracil (also known as fluorouracil or 5-FU). Cisplatin and carboplatin are platinum-based chemotherapy agents that cause DNA crosslinking and damage, leading to apoptosis in rapidly dividing cancer cells. 5-fluorouracil is an antimetabolite and pyrimidine analog that inhibits thymidylate synthase, thereby blocking DNA synthesis and cell division[1][6][7]. This combination is used in the treatment of various cancers—most commonly gastrointestinal, head and neck, gynecological, or other solid tumors—where multi-agent chemotherapy regimens are standard. The inclusion of a placebo indicates this regimen may be used as a control arm in clinical trials.